Related Experiment Video
Updated: Jun 2, 2026
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
Antineoplastic effects of simvastatin in experimental breast cancer
P Kubatka1, K Zihlavniková, K Kajo
1Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic. kubatka@jfmed.uniba.sk
Backgrounds:
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have proven therapeutic and preventive effects on cardiovascular diseases. Preclinical evidence demonstrates tumor-suppressive effects of statins in several human neoplasias, including breast cancer.
Materials And Methods:
In this study, antineoplastic effects of simvastatin in chemoprevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats were evaluated. The drug was dietary administered at two concentrations--18 mg/kg (SIMVA 18) and 180 mg/kg (SIMVA 180).
Results:
Basic parameters of experimental carcinogenesis after long-term simvastatin treatment in animals were assessed. In the SIMVA 180 group, simvastatin significantly suppressed tumour frequency by 80.5% and tumour incidence by 58.5% in comparison to the controls. Higher dose simvastatin non-significantly decreased the mean tumor volume by 23.5%, as well as non-significantly lengthened the latency period by 14.5 days compared to the control animals. Simvastatin, administered at a lower dose did not change parameters of mammary carcinogenesis in comparison to the control group. Simvastatin in both treated groups significantly decreased serum levels of triacylglycerols and VLDL-cholesterol in comparison to the control animals. Compared to the controls, a significant increase in food intake by the animals was recorded in the SIMVA 18 and SIMVA 180 groups. No significant differences in the final body weight gain between the simvastatin-administered and the control group were found.
Conclusion:
This study represents the first report of simvastatin use in experimental mammary carcinogenesis in vivo.
Insights
High-dose simvastatin significantly reduced mammary tumor frequency and incidence in a rat model. This study is the first to investigate simvastatin
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are known for cardiovascular benefits.
- Preclinical studies suggest statins possess tumor-suppressive properties in various cancers, including breast cancer.
Purpose of the Study:
- To evaluate the antineoplastic effects of simvastatin in preventing N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats.
- To assess simvastatin's impact on tumor development and related biochemical parameters in an experimental cancer model.
Main Methods:
- Female rats were administered N-methyl-N-nitrosourea to induce mammary carcinogenesis.
- Dietary simvastatin was administered at two concentrations: 18 mg/kg (SIMVA 18) and 180 mg/kg (SIMVA 180).
- Tumor parameters, serum lipid levels, food intake, and body weight gain were assessed.
Main Results:
- High-dose simvastatin (180 mg/kg) significantly suppressed tumor frequency by 80.5% and tumor incidence by 58.5%.
- The high dose non-significantly reduced mean tumor volume and lengthened latency period; lower dose showed no significant effect.
- Simvastatin significantly decreased serum triacylglycerols and VLDL-cholesterol, and increased food intake, without affecting body weight gain.
Conclusions:
- This study provides the first in vivo evidence of simvastatin's efficacy in experimental mammary carcinogenesis.
- High-dose simvastatin demonstrates significant chemopreventive potential against mammary tumors in rats.
- Simvastatin's lipid-lowering effects may contribute to its observed antineoplastic activity.
